- Cryoport reported a 14% increase in total revenue from continuing operations in Q2 2025.
- Gross margin improved to 47%, up significantly from prior year, with adjusted EBITDA loss narrowing to $0.9 million from $5.6 million a year ago.
- Life Sciences Products revenue increased 8% year-over-year, driven by animal health demand and new product launches.
- Life Sciences Services revenue grew 21% year-over-year, with commercial cell and gene therapy support up 33% and BioStorage/BioServices up 28%.
- MVE segment grew 8% year-over-year with strong margins at 44.9%, driven by animal health and international markets outside China.
Related items and other data are not available for this feed item.
Dafinchi